Natural killer/T-cell lymphoma (NKTCL) is a rare subtype of non-Hodgkin lymphoma (NHL), associated with Epstein-Barr virus (EBV) infection. NKTCLs develop almost exclusively in non-nodal sites with around 80% of cases occurring in the nose, nasopharynx, oropharynx, the Waldeyer’s ring, and parts of the upper aerodigestive tract. Collectively, these are referred to as nasal NK/T-cell lymphomas. The remaining 20% of NKTCLs occur in non-nasal sites and are referred to as non-nasal NK/T-cell lymphomas.
In recent years, the introduction of combined chemotherapy and radiotherapy for localized disease and with the advent of L-asparaginase, the outlook of NK/T-cell lymphomas has improved. However, the prognosis for these patients still remains poor. Further studies are needed to improve the survival rates for these patients.
In this Research Topic, we welcome Original Research, Reviews, and Case Reports focused on the biology of NKTCL, prognostic and predictive biomarkers, and novel therapies.
Natural killer/T-cell lymphoma (NKTCL) is a rare subtype of non-Hodgkin lymphoma (NHL), associated with Epstein-Barr virus (EBV) infection. NKTCLs develop almost exclusively in non-nodal sites with around 80% of cases occurring in the nose, nasopharynx, oropharynx, the Waldeyer’s ring, and parts of the upper aerodigestive tract. Collectively, these are referred to as nasal NK/T-cell lymphomas. The remaining 20% of NKTCLs occur in non-nasal sites and are referred to as non-nasal NK/T-cell lymphomas.
In recent years, the introduction of combined chemotherapy and radiotherapy for localized disease and with the advent of L-asparaginase, the outlook of NK/T-cell lymphomas has improved. However, the prognosis for these patients still remains poor. Further studies are needed to improve the survival rates for these patients.
In this Research Topic, we welcome Original Research, Reviews, and Case Reports focused on the biology of NKTCL, prognostic and predictive biomarkers, and novel therapies.